Category biotech

Arcturus Therapeutics shares plunge 56% after mixed phase 2 CF drug results
Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) tumbled by more than 56% on Wednesday after the company reported interim results from ...
Oct, 22, 2025
3 min read
by Invezz

Evening digest: Trump-Putin talks are stalled, Sarkozy begins prison term, gold crashes
A tense day in global politics and markets: the Trump-Putin summit is in limbo after Moscow refused a Ukraine ceasefire. France’s former president ...
Oct, 21, 2025
3 min read
by Invezz

Is Danaher’s Q3 beat enough to reignite long-term growth for DHR investors?
Danaher stock surged over 7% on Tuesday after the company delivered a solid third-quarter performance, with revenues rising 4.5% to $6.1 billion an...
Oct, 21, 2025
2 min read
by Invezz